Claims for Patent: 7,927,806

Summary for Patent: 7,927,806

Title:	Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
Abstract:	This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
Inventor(s):	Busse; Ursula (Saint-Louis, FR), Chypre; Camille (Annecy, FR), Fradet; Yves (Quebec, CA)
Assignee:	Diagnocure Inc. (Sainte-Foy, CA)
Application Number:	12/635,917
Patent Claims:	1. A method of determining the malignancy status of prostate cells contained in a sample undergoing testing, said method comprising: (a) amplifying PCA3 nucleic acids using RNA templates and a pair of oligonucleotides which amplify across nucleotide positions 26 and 255 of SEQ ID NO:1 and across nucleotide positions 26 and 27 of SEQ ID NO:2, thereby resulting in a collection of amplified nucleic acids, when said PCA3 nucleic acids are present, said collection comprising (i) a PCA3 nucleic acid that comprises an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO:1; and (ii) a PCA3 nucleic acid that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence; and (b) detecting among said collection of amplified nucleic acids (iii) substantially only said PCA3 nucleic acid that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence, and not said PCA3 nucleic acid that comprises said additional sequence, if said sample comprises prostate cancer cells; and (iv) substantially only said PCA3 nucleic acid that comprises said additional sequence between PCA3 exon 3 and PCA3 exon 4a, and not said PCA3 nucleic acid that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence, if prostate cells contained in the sample consist of benign prostate cells associated with BPH, thereby determining the malignancy status of prostate cells contained in said sample. 2. The method of claim 1, wherein said pair of oligonucleotides comprises a first oligonucleotide which binds to or upstream of nucleotide position 26 of SEQ ID NO:1, and a second oligonucleotide which binds to or downstream of nucleotide position 255 of SEQ ID NO:1. 3. The method of claim 1, wherein said pair of oligonucleotides comprises a first oligonucleotide which binds to exon 3 and a second oligonucleotide which binds to exon 4a. 4. The method of claim 1, wherein after step (a) and before step (b) there is an additional step of contacting said amplified nucleic acids with a detectably labelled hybridization probe. 5. The method of claim 4, wherein said detecting in step b) comprises binding with a probe which hybridizes under high stringency conditions to at least 10 consecutive nucleotides of a sequence comprising nucleotides 26 and 27 of SEQ ID NO:2, which define the exon 3-exon 4a junction, wherein said high stringency conditions comprise a hybridization at 65.degree. C. in 5.times.SSC, 5.times.Denhardt's solution, 1% SDS, and 100 .mu.g/ml denatured salmon sperm DNA. 6. The method of claim 5, wherein said probe hybridizes to at least 15 consecutive nucleotides of said exon 3-exon 4a junction. 7. The method of claim 5, wherein said probe hybridizes to at least 20 consecutive nucleotides of said exon 3-exon 4a junction. 8. The method of claim 4, wherein said probe hybridizes to at least 15 consecutive nucleotides of said exon 3-exon 4a junction. 9. The method of claim 4, wherein said probe hybridizes to at least 20 consecutive nucleotides of said exon 3-exon 4a junction. 10. The method of claim 1, wherein said oligonucleotides are at least 10 nucleotides in length. 11. The method of claim 1, wherein said amplifying in step (a) comprises a reaction selected from the group consisting of a nucleic acid sequence-based amplification reaction (NASBA), a polymerase chain reaction (PCR), a transcription-based amplification reaction, a strand displacement amplification (SDA), a ligase chain reaction (LCR), and a Q.beta. replicase reaction. 12. The method of claim 1, wherein said oligonucleotides are at least 12 nucleotides in length. 13. The method of claim 1, wherein said oligonucleotides are at least 15 nucleotides in length. 14. The method of claim 1, wherein said oligonucleotides are at least 20 nucleotides in length. 15. The method of claim 1, wherein said oligonucleotides are at least 18 to about 50 nucleotides in length. 16. The method of claim 1, wherein said oligonucleotides are at least 20 to about 35 nucleotides in length. 17. The method of claim 1, wherein said pair of oligonucleotides comprises a first oligonucleotide binding to a sequence comprised in nucleotides 1 to 26 of SEQ ID NO:1, and a second oligonucleotide binding to a sequence comprised in nucleotides 255 to 506 of SEQ ID NO:1. 18. A method of distinguishing differentially expressed PCA3 nucleic acids that indicate the malignancy status of prostate cells contained in a sample undergoing testing, said method comprising: (a) performing a nucleic acid amplification reaction, using RNAs obtained from prostate cells contained in said sample as templates to amplify PCA3 nucleic acid sequences across nucleotide positions 26 and 255 of SEQ ID NO:1, which respectively define the PCA3 exon 3-intron 3 and intron 3-exon 4a junctions, and nucleotide positions 26 and 27 of SEQ ID NO:2, which define the PCA3 exon 3-exon 4a junction, whereby there are synthesized first and second amplification products; wherein said first amplification product results from an amplification of a first PCA3 RNA that comprises portions of exon 3 and exon 4a sequences and an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO:1, and wherein said second amplification product results from an amplification of a second PCA3 RNA that comprises portions of exon 3 and exon 4a sequences with PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence; and (b) detecting one of said first and second amplification products independent of the other, thereby distinguishing differentially expressed PCA3 nucleic acids that indicate the status of prostate cells contained in said sample. 19. The method of claim 18, wherein said amplification is carried-out with a pair of oligonucleotides comprising a first oligonucleotide which binds to exon 3 and a second oligonucleotide which binds to exon 4a. 20. A kit for determining the malignancy status of prostate cells by distinguishing between a non-malignant PCA3 nucleic acid and a malignant PCA3 nucleic acid in a sample undergoing testing said kit comprising: (a) a pair of oligonucleotides which amplify across nucleotide positions 26 and 255 of SEQ ID NO:1 and across nucleotide positions 26 and 27 of SEQ ID NO:2, thereby resulting in a collection of amplified nucleic acids, when said PCA3 nucleic acids are present, said collection comprising a PCA3 nucleic acid that comprises an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence consisting essentially of nucleotides 27 to 254 of SEQ ID NO:1, and a PCA3 nucleic acid that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence; and (b) a probe hybridizing under high stringency conditions to at least 10 consecutive nucleotides of a nucleic acid comprising nucleotide positions 26 and 27 of SEQ ID NO:2, which define the PCA3 exon 3-exon 4a junction, thereby detecting among said collection of amplified nucleic acids substantially only said PCA3 nucleic acid that comprises PCA3 exon 3 joined to PCA3 exon 4a without including said additional sequence, and not said PCA3 nucleic acid that comprises said additional sequence.

Details for Patent 7,927,806

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-09-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-09-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-09-29